Pharmacoproteomics of obesity: Definitions, role and a case study of dynamics of human plasma proteome

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1363-1365

  Andreev, Victor P ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

adipose tissue; leptin; leptin resistance; obesity; pharmacogenomics; pharmacoproteomics; plasma; proteomics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; CAPSAICIN; CHITOSAN OLIGOSACCHARIDE; LEPTIN; OLIGOSACCHARIDE; PHARMACOPROTEOME; PROTEIN; PROTEOME; RECOMBINANT LEPTIN; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

BLOOD LEVEL; CASE STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOXICITY; ENVIRONMENTAL FACTOR; GENETIC VARIABILITY; HORMONE DEFICIENCY; HUMAN; LEPTIN DEFICIENCY; LIFESTYLE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OBESITY; PHARMACOPROTEOMICS; PROTEIN BLOOD LEVEL; PROTEOME BLOOD LEVEL; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

HUMANS; LEPTIN; OBESITY; PHARMACOGENETICS; PLASMA; PROTEOME; PROTEOMICS;

EID: 80054880042     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.101     Document Type: Review

References (19)

1. Moyses C. Pharmacogenetics, genomics, proteomics: the new frontiers in drug development. Int. J. Pharm. Med. 13(4), 197-202 (1999). (Pubitemid 29419677)
2. Valdes R Jr, Linder MW, Jortani SA. What is next in pharmacogenomics. Translating it to clinical practice. Pharmacogenomics 4(4), 499-505 (2003). (Pubitemid 36857182)
3. Kley N, Ivanov I, Meier-Ewert S. Genomic and proteomics tools for compound mode-of-action studies in drug discovery. Pharmacogenomics 5(4), 395-404 (2004). (Pubitemid 38923653)
4. Paik YK, Graham JE, Jone M, McDonald F, Holmes C, Ozdemir V. Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): pharmacoproteomics and the approaching wave of 'proteomics diagnostics'. Curr. Pharmacogenomics Person. Med. 7, 243-248 (2009).
5. Benet LZ. Pharmacokinetics: basic principles and its use as a tool in drug metabolism. In: Drug Metabolism and Drug Toxicity. Mitchell JR, Horning MG (Eds). Raven Press, NY, USA (1984).
6. Relton CL, Smith GD. Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. PLoS Medicine 7(10), e1000356 (2010).
7. Barcelo-Batllori S, Gomis R. Proteomics in obesity research. Proteomics Clin. Appl. 3, 263-278 (2009).
8. Ong SE, Mann M. Mass spectrometry based proteomics turns quantitative. Nat. Chem. Biol. 5(2), 252-262 (2005).
9. Adachi J, Kumar C, Zhang Y, Mann M. In depth analysis of the adipocytes proteome by mass spectrometry and bioinformatics. Mol. Cell. Proteomics 6, 1257-1273 (2007). (Pubitemid 47099234)
10. Choi JW, Joo JI, Kim DH et al. Proteome changes in rat plasma in response to sibutramine. Proteomics 11, 1300-1312 (2011).
11. Hess S, Chen X. Applications of proteomics to the study of adipose tissue. Methods Mol. Biol. 456, 131-140 (2008).
12. Ahmed M, Neville MJ, Edelmann MJ, Kessler BM, Karpe F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity 18(1), 27-34 (2010).
13. Chen X, Hunt D, Cushman SW, Hess S. Proteomic characterization of thiazolidinedione regulation of obese adipose secretome in Zucker obese rats. Proteomics Clin. Appl. 3, 1099-1111 (2009).
14. Kumar SG, Rahman MA, Lee SH, Hwang HS, Kim HA, Yun JW. Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics 9, 2149-2162 (2009).
15. Joo JJ, Kim DH, Choi JW, Yun JW. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J. Proteome Res. 9, 2977-2987 (2010).
16. Andreev VP, Dwivedi RC, Paz-Filho G et al. Dynamics of plasma proteome during leptin replacement therapy in genetically-based leptin deficiency. Pharmacogenomics J. 11, 174-190 (2011).
17. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. Natl Acad. Sci. USA 101, 4531-4536 (2004). (Pubitemid 38437445)
18. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994). (Pubitemid 24365442)
19. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292-295 (1996). (Pubitemid 26033933)